Biopharmaceuticals
Prosensa Receives (GBP)7.5M Milestone Payment as Part of Its Program with GlaxoSmithKline in Duchenne Muscular Dystrophy
Published in Gene Therapy Weekly, October 28th, 2010
Prosensa, the Dutch biopharmaceutical company focusing on RNA modulating therapeutics, has announced that it received a £7.5m milestone payment from GlaxoSmithKline (GSK) as a result of achieving a data milestone in its Phase IIa open label extension trial of GSK2402968 (PRO051), being developed to treat Duchenne Muscular Dystrophy (DMD) under its agreement with GSK. The milestone payment was based upon achievement of a successful safety review, with no serious safety signals observed.
GSK2402968 (PRO051) is an investigational antisense oligonucleotide which induces exon skipping of exon 51. The six-month data from the open label Phase IIa extension study in 12...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2010-10-28)
More Articles from Gene Therapy Weekly
- Phagocytes
Data on phagocytes described by researchers at University of Pennsylvania - Angiology
New angiology data have been reported by scientists at University of Florida, Powell Gene Therapy Center - Skin Infection
New findings in skin infection described from University of California - Collagen Type XVIII
Recent findings from Harbin Medical University highlight research in collagen type XVIII - Gene Therapy
Recent findings from Wadsworth Center, Department of Health highlight research in gene therapy - Gene Therapy
Report summarizes gene therapy study findings from City of Hope National Medical Center - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
